Overall, our observations identify MC4-R agonism as a viable target for the treatment of obesity and possibly also the insulin resistance which is a central factor involved in the pathogenesis of type 2 diabetes. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.